The Lower Drug Costs for Families Act (H.R. 2554) would expand prescription drug inflation rebates to the commercial market, requiring drug manufactures to pay back excess price increases to lower costs for all insured Americans.
Expand prescription drug inflation rebates to the commercial market so drug manufacturers must pay back excess price increases.
Occurrences
H.R.25524 - Lower Drug Costs for Families Act ... To amend title XVIII of the Social Security Act to apply prescription drug inflation rebates to drugs furnished in the commercial market and to change the base year for rebate calculations.
Evidence
The member's official homepage latest-news block in the lookback window lists June 15, 2026 DACA remarks, June 10, 2026 Social Security oversight, and June 9, 2026 digital-asset hearing remarks; it does not show any prescription-drug rebate action or commercial-market inflation-rebate announcement.
The official health page states a broad commitment to affordable health care and links recent health posts about ACA tax credits, HHS cuts, and provider support, but it contains no reference to expanding prescription-drug inflation rebates into the commercial market.
Assessments
The available evidence does not show that Steven Horsford delivered this specific policy outcome or materially advanced legislation that enacted commercial-market prescription-drug inflation rebates. The cited official House homepage and health-policy page show general health-care activity but no documented action on this precise rebate expansion. Because the record provided is mainly negative evidence of no visible delivery signal, the claim is best scored as unresolved rather than delivered, partial, or never.